About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Financial Data and Key Metrics Changes - In Q4 2025, CVS Health reported adjusted operating income of $2.6 billion and adjusted earnings per share (EPS) of $1.09, with full-year adjusted EPS of $6.75 and operating cash flow of $10.6 billion, exceeding initial expectations by approximately 15% [5][6][24]. - Full-year revenue for 2025 was over $400 billion, with Q4 revenue exceeding $105 billion, an increase of over 8% year-over-year [23][24]. Business Line Data and Key Metrics Changes - The healthcare benefits segment generated over $36 billion in revenue for Q4, a 10% increase year-over-year, but reported an adjusted operating loss of $676 million due to changes in the Medicare Part D program [25][26]. - The health services segment saw revenues of over $51 billion, a 9% increase year-over-year, with adjusted operating income of approximately $1.9 billion [28]. - The pharmacy and consumer wellness segment generated nearly $38 billion in revenue, a 12% increase year-over-year, with same-store pharmacy sales growing over 19% [29][30]. Market Data and Key Metrics Changes - The company ended 2025 with approximately 26.6 million medical members, a slight decline from the previous year, primarily due to losses in individual exchange and government businesses [25][26]. - Aetna received the inaugural Press Ganey Health Plan of the Year award, recognizing its high-quality offerings and technological innovation [7]. Company Strategy and Development Direction - CVS Health aims to simplify the healthcare experience and make it more affordable, with a commitment to becoming America's most trusted healthcare company [5]. - The company is focused on improving margins in its Medicare business while advocating for better funding to ensure adequate access for seniors [8][40]. - CVS Health is committed to leveraging its diversified business model to unlock earnings power and drive shareholder value [6][21]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum entering 2026, expecting another strong year of progress despite elevated medical cost trends [33][34]. - The company remains focused on addressing the challenges of cost, complexity, and fragmentation in the U.S. healthcare system [15][21]. Other Important Information - CVS Health's pharmacy businesses are adapting to regulatory changes while maintaining durable margins, emphasizing the importance of transparency and competition in the pharmaceutical supply chain [12][19]. - The company has successfully transitioned to a cost-based reimbursement model, enhancing transparency and stability in the pharmacy market [14][31]. Q&A Session Questions and Answers Question: Impact of Medicare Advantage rates on margins - Management acknowledged the Advanced Rate Notice's impact on Aetna but remains committed to improving Medicare Advantage margins and believes the business is well-positioned despite the preliminary rates [37][39][45]. Question: Regulatory impact on PBM negotiations - Management indicated that while they cannot discuss specifics regarding the FTC, they believe the PBM value remains intact and that they are prepared for upcoming regulatory changes [51][53]. Question: Medicaid rates and expectations for 2026 - Management reported that the Medicaid business is performing in line with expectations and emphasized ongoing advocacy for adequate rates while maintaining operational excellence [72][74].

CVS Health (NYSE:CVS) Q4 2025 Earnings call February 10, 2026 08:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchBrian Newman - CFODavid Joyner - Chairman and CEOEdward DeVaney - EVP and PresidentLawrence McGrath - EVP of Capital MarketsLisa Gill - Managing DirectorPrem Shah - Chief Pharmacy Officer and President of Pharmacy and Consumer WellnessSree Chaguturu - EVP and President of Healthcare DeliverySteve Nelson - EVP and President of AetnaConference Call ParticipantsAnn Hynes - Equit ...

CVS Health (NYSE:CVS) Q4 2025 Earnings call February 10, 2026 08:00 AM ET Speaker7Hello and welcome to CVS Health's fourth quarter 2025 earnings call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the question-and-answer session. As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call to Larry McGrath, Chief Strategy Officer. Larry, ...

CVS Health delivered a stronger-than-expected fourth quarter, beating Wall Street estimates on both earnings and revenue as the company presses ahead with a multi-year turnaround. The results underlin... ...

CVS Health (NYSE: CVS) delivered a solid revenue beat in Q4 2025, though adjusted earnings declined year-over-year despite exceeding Wall Street expectations. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

格隆汇2月10日｜医疗保险公司CVS Health公布2025年第四季度业绩，营收同比增长超8%至1057亿美 元，高于分析师平均预期的1035.9亿美元；调整后每股收益同比下滑超8%至1.09美元，亦超过分析师预 期的0. 99美元。展望2026年，公司重申年收入至少达到4000亿美元的预期，维持调整后每股收益介乎7 至7.2美元的预期。 ...

Fourth Quarter 2025 February 10, 2026 Earnings Conference Call J. David Joyner Chair and Chief Executive Officer Brian O. Newman Executive Vice President and Chief Financial Officer 1 ©2026 CVS Health and/or one of its affiliates. Confidential and proprietary. Cautionary Statement concerning forward-looking statements This presentation includes forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS He ...

VANCOUVER, BC – TheNewswire - FEBRUARY 9th, 2026 – AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY) is pleased to announce that its previously announced non-brokered private placement of up to CAD $175,000 at $0.105 per unit consisting of up to 1,666,666 units is now fully subscribed. Each unit is comprised of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for a ...